SNV4818 in Participants With Advanced Solid Tumors

Condition(s) studied

Investigational drug(s) / intervention(s)

SNV4818: SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.

Fulvestrant: Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)

Palbociclib: Palbociclib tablets will be administered by mouth on days 1-21 of a 28 day cycle. The Palbociclib starting dose will be 125 mg once-daily

Study summary

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

Eligibility

Primary outcome measure(s)

• Incidence of dose limiting toxicities (DLTs) — First 28 days of study treatment
  -Number of participants experiencing protocol-defined DLTs (Part 1A and 2A only)
• Treatment Emergent Adverse Events (TEAEs) — From first SNV4818 dose through approximately 30 days following the last SNV4818 dose
  Incidence and frequency of TEAEs

Trial sites (12)

On this site

Other trials for the same condition